The Vaccine Group appoints Jeremy Salt as CEO

RNS Number : 5415X

Frontier IP Group plc

06 May 2021

 

Reach - a non-regulatory announcement

AIM: FIPP

06 May 2021

Frontier IP Group Plc

("Frontier IP" or the "Group") 

Portfolio news - The Vaccine Group appoints GALVmed Chief Scientific Officer Jeremy Salt as Chief Executive Officer

Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company The Vaccine Group ("TVG" or the "Company") has appointed Dr Jeremy Salt as Chief Executive Officer.

Jeremy has extensive experience in senior roles in animal healthcare across organisations in the commercial and not-for-profit sectors. He is joining TVG from GALVmed, a not-for-profit organisation that develops and makes available livestock vaccines, medicines and diagnostics for small-scale livestock producers, where he was Chief Scientific Officer. GALVmed is funded by the UK government's Foreign, Commonwealth & Development Office through UKAID and the Bill & Melinda Gates Foundation.

Before GALVmed, he was the director of Biologicals Research & Development for the Europe, Africa and Middle East arm of the world's biggest animal health group Zoetis, and previously the vaccines division of Pfizer Animal Health. Jeremy has completed a PhD in the immunology of foot and mouth virus persistence.

As TVG Chief Executive, Jeremy will be responsible for the continued development and commercialisation of the Company's novel vaccine platform technology, which is being used to develop a wide range of different vaccines to combat zoonotic and economically-damaging diseases. These include vaccines to combat COVID-19, Ebola, Lassa fever, African Swine Fever, porcine respiratory and reproductive virus (PRRSV), and bovine tuberculosis.

The University of Plymouth spin out and its international partners have so far been awarded more than £9 million in grants from the UK, US and Chinese governments. It has also signed its first commercial deal with ECO Animal Health Group plc and The Pirbright Institute to develop vaccine candidates to combat PRRSV, one of the most economically damaging diseases to the pig industry.  Frontier IP holds a 17 per cent equity stake in TVG.

Jeremy Salt, Chief Executive Officer of The Vaccine Group said: "I am delighted to be taking this leadership role with The Vaccine Group at this important time in its development. The COVID-19 pandemic has raised the profile of vaccines as a key component of infectious disease control. The importance of multiple technological approaches to vaccine development has been shown to be critical. The Vaccine Group is well-positioned to contribute to this market with its novel vaccine platform technologies."

Neil Crabb, Frontier IP Chief Executive Officer, said: "Jeremy's experience in animal healthcare, including vaccines, across several major organisations will be invaluable to The Vaccine Group as it evolves its technology, brings it to market and develops into a successful company. We are working to strengthen management teams across our portfolio, and we are very pleased Jeremy has decided to join TVG. We very much look forward to working with him to make the Company the success it deserves to be."

ENQUIRIES

Frontier IP Group Plc	T: 020 7332 2338
Neil Crabb, Chief Executive Andrew Johnson, Communications & Investor Relations Company website: www.frontierip.co.uk	[e-mail] M: 07464 546 025
Fieldwork Robotics Ltd Rui Andres, Chief Executive Allenby Capital Limited (Nominated Adviser)	[e-mail] T: 0203 328 5656
Nick Athanas / George Payne

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

Frontier IP is the commercialisation partner for the University of Plymouth.

ABOUT THE UNIVERSITY OF PLYMOUTH

The University of Plymouth is renowned for high quality, internationally leading education, research and innovation.

With a mission to Advance Knowledge and Transform Lives, Plymouth is a *top 50 research university with clusters of world class research across a wide range of disciplines including marine science and engineering, medicine, cybersecurity and psychology. A three-time winner of the Queen's Anniversary Prize for Higher and Further Education, most recently in 2020 in respect of its pioneering research on microplastics pollution in the oceans and its impact on the environment and changing behaviour, the University continues to grow in stature and reputation.

It has a strong track record for teaching and learning excellence and has one of the highest numbers of National Teaching Fellows of any UK university. With over 19,000 students, and a further 9,500 studying for a Plymouth degree at partner institutions in the UK and around the world, and over 135,000 alumni pursuing their chosen careers globally, it has a growing global presence.

http://www.plymouth.ac.uk

* Research Fortnight Research Power League Table 2014.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.  Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

END

 

 

NRADKQBBKBKBDPK